Nasdaq IPOs

Opthea, an Australian Phase 3 biotech developing VEGF inhibitors for wet AMD, announced terms for its IPO on Friday. The South Yarra, Australia-based company plans to raise $161 million by offering 9.3 million ADSs at $17.26, the as-converted last close of its shares on the ASX (

Atea Pharmaceuticals, a clinical stage biotech developing therapies for COVID-19 and other viral infections, filed on Friday with the SEC to raise up to $100 million in an initial public offering. Atea Pharmaceuticals is developing antiviral therapeutics for life-threatening&nbsp

Vivos Therapeutics, which is developing medical devices for sleep disordered breathing, filed on Friday with the SEC to raise up to $20 million in an initial public offering. The Highlands Ranch, CO-based company plans to raise $20 million by offering 3.3 million shares at a pric

Ajax I, a blank check company formed by Och-Ziff's Daniel Och and MSD Capital's Glenn Fuhrman, filed on Friday with the SEC to raise up to $750 million in an initial public offering. The New York, NY-based company plans to raise $750 million by offering 75 million units at $10. E

Mudrick Capital Acquisition II, the second blank check company formed by distressed debt investor Jason Mudrick to acquire a post-bankruptcy business, filed on Friday with the SEC to raise up to $300 million in an initial public offering. The New York, NY-based company plans

Intrusion, which provides a family of software products for enterprise security, raised $25 million by offering 3.1 million shares (65% primary) at $8, below the last close of its shares on the OTCQB (INTZ). At pricing, the company commands a market value of $135 million. Intrusi

Praxis Precision Medicines, a Phase 2 biotech developing therapies for CNS disorders using genetic insights, announced terms for its IPO on Friday. The Cambridge, MA-based company plans to raise $126 million by offering 7.4 million shares at a price range of $16 to $18. At the mi

Consonance-HFW Acquisition, a blank check company formed by Consonance Capital targeting the life science industry, filed on Friday with the SEC to raise up to $100 million in an initial public offering. The Princeton, NJ-based company plans to raise $100 million by offering 10 m

Shattuck Labs, a Phase 1 biotech developing novel dual-sided fusion protein therapies for cancer, raised $202 million by offering 11.9 million shares at $17, above the range of $14 to $16. The company offered 1.9 million more shares than anticipated. At pricing, the company raise

Sports Ventures Acquisition, a blank check company targeting sports, media, and entertainment, filed on Friday with the SEC to raise up to $200 million in an initial public offering. The Bal Harbour, FL-based company plans to raise $200 million by offering 20 million units a

iHuman, which provides edutainment products for children in China, raised $84 million by offering 7 million ADSs at $12, within the range of $11 to $13. iHuman plans to list on the NYSE under the symbol IH. Credit Suisse, Citi, Tiger Brokers, CMB International Capital and CITIC C

Spruce Biosciences, a Phase 2 biotech developing a novel therapy for rare endocrine disorders, raised $90 million by offering 6 million shares at $15, within the range of $14 to $16. The company offered 1 million more shares than anticipated. At pricing, the company raised 20% mo

Landcadia Holdings III, the third blank check company formed by the CEOs of Landry's and Jefferies to acquire an entertainment business, raised $500 million by offering 50 million units at $10. Each unit consists of one share of common stock and one-third of a warrant, exercisabl

Kronos Bio, a Phase 2 biotech developing kinase inhibitors for leukemia and solid tumors, raised $250 million by offering 13.2 million shares at $19, above the range of $16 to $18. The company originally planned to offer 10.3 million shares at the same range before revising its t

Social Capital Hedosophia Holdings VI, the sixth blank check company formed by Social Capital and Hedosophia targeting a tech business, raised $1.0 billion by offering 100 million units at $10. Each unit consists of one share of common stock and one-quarter of a warrant, exercisa

Social Capital Hedosophia Holdings V, the fifth blank check company formed by Social Capital and Hedosophia targeting a tech business, raised $700 million by offering 70 million units at $10. The company offered 5 million more units than anticipated. Each unit consists of one sha

Social Capital Hedosophia Holdings IV, the fourth blank check company formed by Social Capital and Hedosophia targeting a tech business, raised $400 million by offering 40 million units at $10. The company offered 5 million more units than anticipated. Each unit consists of one s

Thayer Ventures Acquisition, a blank check company formed by Thayer Ventures targeting the travel and transportation industries, filed on Thursday with the SEC to raise up to $175 million in an initial public offering. The Valencia, CA-based company plans to raise $175 milli

Forest Road Acquisition, a blank check company formed by Forest Road targeting TMT businesses, filed on Thursday with the SEC to raise up to $250 million in an initial public offering. The New York, NY-based company plans to raise $250 million by offering 25 million units at $10.

InMed Pharmaceuticals, a clinical stage biotech developing cannabinoid-based products, announced terms for its IPO on Thursday. The Vancouver, Canada-based company plans to raise $10 million by offering 2.4 million shares at $4.13, above the last close of its shares on the OTCQX